167 related articles for article (PubMed ID: 25949920)
1. Tregs activated by bispecific antibodies: Killers or suppressors?
Koristka S; Cartellieri M; Arndt C; Feldmann A; Seliger B; Ehninger G; Bachmann MP
Oncoimmunology; 2015 Mar; 4(3):e994441. PubMed ID: 25949920
[TBL] [Abstract][Full Text] [Related]
2. Retargeting T cells to GD2 pentasaccharide on human tumors using Bispecific humanized antibody.
Xu H; Cheng M; Guo H; Chen Y; Huse M; Cheung NK
Cancer Immunol Res; 2015 Mar; 3(3):266-77. PubMed ID: 25542634
[TBL] [Abstract][Full Text] [Related]
3. Tumor-infiltrating lymphocytes can be activated in situ by using in vivo activants plus F(ab')2 bispecific antibodies.
Thibault C; Nelson H; Chapoval AI
Int J Cancer; 1996 Jul; 67(2):232-7. PubMed ID: 8760593
[TBL] [Abstract][Full Text] [Related]
4. Targeted cancer immunotherapy via combination of designer bispecific antibody and novel gene-engineered T cells.
Urbanska K; Lynn RC; Stashwick C; Thakur A; Lum LG; Powell DJ
J Transl Med; 2014 Dec; 12():347. PubMed ID: 25496493
[TBL] [Abstract][Full Text] [Related]
5. In vivo studies using bispecific antibodies (anti-CD3 x anti-idiotype) and CD28-induced costimulation in the BCL1 lymphoma.
Demanet C; Brissinck J; De Jonge J; Thielemans K
J Hematother; 1995 Oct; 4(5):363-8. PubMed ID: 8581370
[TBL] [Abstract][Full Text] [Related]
6. Activation of T cell cytotoxicity against autologous common acute lymphoblastic leukemia (cALL) blasts by CD3xCD19 bispecific antibody.
Csóka M; Strauss G; Debatin KM; Moldenhauer G
Leukemia; 1996 Nov; 10(11):1765-72. PubMed ID: 8892680
[TBL] [Abstract][Full Text] [Related]
7. Retargeting of human regulatory T cells by single-chain bispecific antibodies.
Koristka S; Cartellieri M; Theil A; Feldmann A; Arndt C; Stamova S; Michalk I; Töpfer K; Temme A; Kretschmer K; Bornhäuser M; Ehninger G; Schmitz M; Bachmann M
J Immunol; 2012 Feb; 188(3):1551-8. PubMed ID: 22184723
[TBL] [Abstract][Full Text] [Related]
8. Retargeting of regulatory T cells to surface-inducible autoantigen La/SS-B.
Koristka S; Cartellieri M; Arndt C; Bippes CC; Feldmann A; Michalk I; Wiefel K; Stamova S; Schmitz M; Ehninger G; Bornhäuser M; Bachmann M
J Autoimmun; 2013 May; 42():105-16. PubMed ID: 23352111
[TBL] [Abstract][Full Text] [Related]
9. MUC1-specific targeting immunotherapy with bispecific antibodies: inhibition of xenografted human bile duct carcinoma growth.
Katayose Y; Kudo T; Suzuki M; Shinoda M; Saijyo S; Sakurai N; Saeki H; Fukuhara K; Imai K; Matsuno S
Cancer Res; 1996 Sep; 56(18):4205-12. PubMed ID: 8797593
[TBL] [Abstract][Full Text] [Related]
10. The preparation of VEGFR1/CD3 bispecific antibody and its specific cytotoxicity against VEGFR1-positive breast cancer cells.
Tang P; Li L; Zhou Y; Shen CC; Kang YH; Yao YQ; Yi C; Gou LT; Yang JL
Biotechnol Appl Biochem; 2014; 61(4):376-84. PubMed ID: 24329807
[TBL] [Abstract][Full Text] [Related]
11. The apoptotic and proliferative fate of cytokine-induced killer cells after redirection to tumor cells with bispecific Ab.
Kornacker M; Verneris M; Kornacker B; Ganten T; Scheffold C; Negrin R
Cytotherapy; 2006; 8(1):13-23. PubMed ID: 16627341
[TBL] [Abstract][Full Text] [Related]
12. ATTACK, a novel bispecific T cell-recruiting antibody with trivalent EGFR binding and monovalent CD3 binding for cancer immunotherapy.
Harwood SL; Alvarez-Cienfuegos A; Nuñez-Prado N; Compte M; Hernández-Pérez S; Merino N; Bonet J; Navarro R; Van Bergen En Henegouwen PMP; Lykkemark S; Mikkelsen K; Mølgaard K; Jabs F; Sanz L; Blanco FJ; Roda-Navarro P; Alvarez-Vallina L
Oncoimmunology; 2017; 7(1):e1377874. PubMed ID: 29296540
[TBL] [Abstract][Full Text] [Related]
13. Bispecific single-chain antibodies as effective tools for eliminating epithelial cancer cells from human stem cell preparations by redirected cell cytotoxicity.
Maletz K; Kufer P; Mack M; Raum T; Pantel K; Riethmüller G; Gruber R
Int J Cancer; 2001 Aug; 93(3):409-16. PubMed ID: 11433407
[TBL] [Abstract][Full Text] [Related]
14. Bispecific anti-idiotype/anti-CD3 antibody therapy of murine B cell lymphoma.
Weiner GJ; Hillstrom JR
J Immunol; 1991 Dec; 147(11):4035-44. PubMed ID: 1834746
[TBL] [Abstract][Full Text] [Related]
15. Human derived dimerization tag enhances tumor killing potency of a T-cell engaging bispecific antibody.
Ahmed M; Cheng M; Cheung IY; Cheung NK
Oncoimmunology; 2015 Apr; 4(4):e989776. PubMed ID: 26137406
[TBL] [Abstract][Full Text] [Related]
16. Bispecific monoclonal antibody therapy of B-cell malignancy.
Weiner GJ; De Gast GC
Leuk Lymphoma; 1995 Jan; 16(3-4):199-207. PubMed ID: 7719227
[TBL] [Abstract][Full Text] [Related]
17. Bispecific antibody does not induce T-cell death mediated by chimeric antigen receptor against disialoganglioside GD2.
Hoseini SS; Dobrenkov K; Pankov D; Xu XL; Cheung NK
Oncoimmunology; 2017; 6(6):e1320625. PubMed ID: 28680755
[TBL] [Abstract][Full Text] [Related]
18. Potent and selective antitumor activity of a T cell-engaging bispecific antibody targeting a membrane-proximal epitope of ROR1.
Qi J; Li X; Peng H; Cook EM; Dadashian EL; Wiestner A; Park H; Rader C
Proc Natl Acad Sci U S A; 2018 Jun; 115(24):E5467-E5476. PubMed ID: 29844189
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of bispecific monoclonal antibody (bsAb)-targeted cytolysis by human anti-mouse antibodies in ovarian carcinoma patients treated with bsAb-targeted activated T-lymphocytes.
Lamers CH; Gratama JW; Warnaar SO; Stoter G; Bolhuis RL
Int J Cancer; 1995 Feb; 60(4):450-7. PubMed ID: 7829257
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of Fc gamma receptor mediated T-cell activation by two purified CD3 x CD19 bispecific monoclonal antibodies with hybrid Fc domains.
Haagen IA; Geerars AJ; Bast EJ; de Gast GC; van de Winkel JG; de Lau WB
Ther Immunol; 1994 Oct; 1(5):279-87. PubMed ID: 7584502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]